Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss

NCT07446998 on ClinicalTrials.gov · last registry update 2026-09-04

An unusually large phase 2: 239 participants, more than double the 110 typical for the stage. Due to report October 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: To determine the effect of enobosarm in combination with semaglutide on total body weight compared to semaglutide alone. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all. The registry entry has been edited 2 times since then.

Status: ACTIVE_NOT_RECRUITING
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Veru Inc.
Sponsor type: Industry
Enrollment: 239
Started: 2026-03-26
Primary completion: 2027-10 estimated

Observed history

Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.

Detected	Change	Detail
2026-09-04	Status changed	RECRUITING → ACTIVE_NOT_RECRUITING
2026-09-04	Enrollment changed	200 → 239 (+39) participants

Primary outcome

To determine the effect of enobosarm in combination with semaglutide on total body weight compared to semaglutide alone.

Conditions studied

Obesity & Overweight · Mobility Disability · HOMA-IR

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.